Skip to main content
Premium Trial:

Request an Annual Quote

Crown Hosting Wins £1.3M Genomics England Data Contract

NEW YORK – Genomics England has awarded a data-hosting contract worth nearly £1.3 million ($1.8 million) to Crown Hosting Data Centres, a cloud computing firm serving public-sector agencies in the UK.

Crown Hosting Data Centres, based in the southwestern England town of Corsham, will provide unspecified data storage services to Genomics England for a 32-month period, running through February 2024, according to an award notice on a UK government website last week. Neither Crown Hosting nor Genomics England issued press releases about the award.

Neither entity responded to a request for comment before deadline.

Crown Hosting is a joint venture between the UK government's Cabinet Office and Ark Data Centres specifically set up to host public-sector data in Britain.

Genomics England already contracts with Amazon Web Services and, through a distributed file system provided by WekaIO, Google Cloud. It migrated data to the WekaIO platform from British cloud host UKCloud.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.